X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2056) 2056
Book Review (136) 136
Publication (103) 103
Book Chapter (32) 32
Dissertation (28) 28
Conference Proceeding (22) 22
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1494) 1494
animals (1378) 1378
6-ohda (1299) 1299
neurosciences (1188) 1188
rats (1123) 1123
male (858) 858
parkinson's disease (847) 847
dopamine (590) 590
6-hydroxydopamine (507) 507
parkinsons-disease (458) 458
rats, sprague-dawley (437) 437
oxidopamine (396) 396
disease models, animal (385) 385
dopamine - metabolism (372) 372
substantia-nigra (341) 341
neurons (316) 316
oxidopamine - toxicity (314) 314
rats, wistar (288) 288
female (287) 287
pharmacology & pharmacy (275) 275
humans (249) 249
6-ohda lesions (245) 245
striatum (241) 241
rat (235) 235
basal ganglia (234) 234
brain (227) 227
neurology (226) 226
corpus striatum - drug effects (220) 220
parkinson’s disease (220) 220
motor activity - drug effects (207) 207
corpus striatum - metabolism (200) 200
mice (197) 197
tyrosine 3-monooxygenase - metabolism (192) 192
substantia nigra (191) 191
oxidative stress (188) 188
oxidopamine - pharmacology (179) 179
substantia nigra - drug effects (172) 172
analysis (170) 170
mptp (170) 170
behavior, animal - drug effects (166) 166
neurons - drug effects (160) 160
biochemistry & molecular biology (156) 156
dose-response relationship, drug (155) 155
neuroprotection (155) 155
immunohistochemistry (151) 151
l-dopa (151) 151
substantia nigra - metabolism (147) 147
dopamine - physiology (145) 145
neurons - metabolism (142) 142
behavioral sciences (139) 139
time factors (138) 138
6-ohda lesion (129) 129
apoptosis (122) 122
in-vivo (116) 116
substantia nigra - pathology (115) 115
nervous system (112) 112
phenols (112) 112
neuroprotective agents - pharmacology (111) 111
apomorphine - pharmacology (110) 110
dopaminergic-neurons (110) 110
parkinsonian disorders - chemically induced (109) 109
neurodegenerative diseases (108) 108
cell biology (107) 107
hydroxydopamines - pharmacology (106) 106
parkinsonian disorders - physiopathology (105) 105
rotation (105) 105
rats, inbred strains (103) 103
movement disorders (102) 102
amphetamine (100) 100
parkinson disease - metabolism (100) 100
biomedicine (99) 99
nigrostriatal pathway (98) 98
parkinsonian disorders - metabolism (98) 98
subthalamic nucleus (95) 95
clinical neurology (94) 94
tyrosine hydroxylase (94) 94
expression (92) 92
neurotrophic factor (92) 92
parkinson disease - physiopathology (92) 92
rotational behavior (92) 92
parkinson disease - drug therapy (91) 91
parkinson disease - pathology (91) 91
dopamine agonists - pharmacology (90) 90
parkinsonian disorders - drug therapy (90) 90
analysis of variance (88) 88
model (88) 88
amphetamine - pharmacology (87) 87
apomorphine (86) 86
corpus striatum - physiology (86) 86
neurotoxicity (86) 86
disease (85) 85
pc12 cells (85) 85
rat model (85) 85
stereotyped behavior - drug effects (84) 84
brain - metabolism (83) 83
motor activity - physiology (82) 82
parkinsons disease (82) 82
corpus striatum - pathology (81) 81
microdialysis (81) 81
parkinson disease (81) 81
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2083) 2083
Chinese (12) 12
Spanish (10) 10
Korean (5) 5
French (4) 4
Russian (3) 3
Japanese (2) 2
Portuguese (2) 2
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuropharmacology, ISSN 0028-3908, 06/2019, Volume 151, pp. 98 - 111
Noradrenergic degeneration in the (LC) seems a convergent neuropathological marker of different neurodegenerative diseases. Herein, we investigated the... 
6-OHDA | Depression | Memory | Locus coeruleus | Olfaction | Apoptosis
Journal Article
Neuroscience Letters, ISSN 0304-3940, 05/2018, Volume 675, pp. 74 - 82
Parkinson's disease (PD) is a progressive neurodegenerative motor disorder characterized by the degeneration of dopaminergic nigrostriatal neurons. Levodopa... 
receptor antagonist | 6-OHDA | Parkinson's disease | Index Medicus
Journal Article
Neuroscience Letters, ISSN 0304-3940, 05/2018, Volume 675, pp. 74 - 82
Parkinson’s disease (PD) is a progressive neurodegenerative motor disorder characterized by the degeneration of dopaminergic nigrostriatal neurons. Levodopa (... 
6-OHDA | Parkinson’s disease | A2A receptor antagonist
Journal Article
11/2009
Parkinson’s disease (PD) is a debilitating movement disorder associated with the death of dopaminergic nigrostriatal neurons. In addition to dopamine... 
SAP97 | Parkinson's | striatum | 0472 | 6-OHDA-lesioned
Dissertation
Neuroscience research, ISSN 0168-0102, 05/2019
Unilateral injection of 6-hydroxydopamine (6-OHDA) is commonly used to generate a rodent model of Parkinson's disease (PD). Although motor deficits of the... 
Journal Article
Cerebral Cortex, ISSN 1047-3211, 04/2019, Volume 29, Issue 4, pp. 1752 - 1766
In Parkinson’s disease, the degeneration of the midbrain dopaminergic neurons is consistently associated with modified metabolic activity in the cerebellum.... 
motor cortex | electrophysiology | optogenetics | 6-OHDA | Original | cerebellum | Parkinson’s disease
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 05/2016, Volume 36, Issue 21, pp. 5686 - 5698
Journal Article
Behavioural Brain Research, ISSN 0166-4328, 09/2018, Volume 350, pp. 109 - 115
The aim of this study was to evaluate etazolate against depression-like behavior and, learning and memory impairment induced by 6- hydroxydopamine (6-OHDA) rat... 
Oxidative stress | BDNF | Memory | Etazolate | 6-OHDA | Maze | Parkinson’s disease
Journal Article
Toxicology in Vitro, ISSN 0887-2333, 10/2019, Volume 60, pp. 400 - 411
Neuronal exposure to 6-hydroxydopamine (6-OHDA), a hydroxylated analog of dopamine, constitutes a very useful strategy for studying the molecular events... 
Oxidative stress | 6-OHDA | Neurotoxicity | Inflammation | Phosphatidic acid | Index Medicus
Journal Article
Neuroscience, ISSN 0306-4522, 2015, Volume 300, pp. 246 - 253
Highlights • The infusion of 6-OHDA was able to promote a depressive-like behavior in rats. • 6-OHDA-lesioned rats exhibited a reduction in the levels of... 
Neurology | piroxicam | 6-OHDA | depression | Parkinson’s disease
Journal Article
Neuroscience, ISSN 0306-4522, 12/2017, Volume 367, pp. 34 - 46
Parkinson’s disease is a common, debilitating, neurodegenerative disorder for which the current gold standard treatment, levodopa (L-DOPA) is symptomatic.... 
6-OHDA | Parkinsons's disease | locomotor activity | neuro-restoration | zebrafish | immunohistochemistry
Journal Article
Behavioural Brain Research, ISSN 0166-4328, 04/2018, Volume 341, pp. 135 - 145
Previous studies showed the loss of dopaminergic neurons directly leads to both changes in firing rate and neuronal synchrony in the striatum by... 
Electrophysiology | 6-OHDA mouse model | Dopamine | Movement | striatum | Parkinson’s disease
Journal Article
Behavioural Brain Research, ISSN 0166-4328, 04/2018, Volume 341, pp. 135 - 145
Previous studies showed the loss of dopaminergic neurons directly leads to both changes in firing rate and neuronal synchrony in the striatum by... 
Electrophysiology | 6-OHDA mouse model | Dopamine | Movement | Parkinson's disease | striatum | PROJECTION NEURONS | FAST-SPIKING INTERNEURONS | NEUROSCIENCES | BASAL GANGLIA OUTPUT | SUBTHALAMIC NUCLEUS | BETA-BAND OSCILLATIONS | GABAERGIC INTERNEURONS | MOTOR CORTEX | BEHAVIORAL SCIENCES | DOPAMINE DEPLETION | DEEP BRAIN-STIMULATION | 6-OHDA LESION
Journal Article
Neuroscience, ISSN 0306-4522, 10/2017, Volume 362, pp. 141 - 151
Brain iron accumulation is a common feature shared by several neurodegenerative disorders including Parkinson’s disease. However, what produces this... 
brain-iron | 6-OHDA | blood–brain barrier | MRI | microglia
Journal Article
Neuroscience, ISSN 0306-4522, 2014, Volume 288, pp. 59 - 72
Highlights • A distinct expression of Nogo-A was detected in the ventral mesencephalon. • Fifty percent of dopaminergic neurons in the substantia nigra... 
Neurology | midbrain | Nogo-A | 6-OHDA lesion | Parkinson’s disease
Journal Article
Neuroscience, ISSN 0306-4522, 09/2017, Volume 359, pp. 8 - 16
Recently, alternative drug therapies for Parkinson’s disease (PD) have been investigated as there are many shortcomings of traditional dopamine-based therapies... 
selective and sustained attention | methylene blue | 6-OHDA | neuroprotection | disengagement behavior
Journal Article
by Jing, X and Shi, H and Zhang, C and Ren, M and Han, M and Wei, X and Zhang, X and Lou, H
Neuroscience, ISSN 0306-4522, 2014, Volume 286, pp. 131 - 140
Journal Article
Neuroscience, ISSN 0306-4522, 2017, Volume 356, pp. 229 - 241
Highlights • FGF18 significantly ameliorates movement impairment in 6-OHDA-induced rat model. • FGF18 treatment prevents 6-OHDA-induced dopaminergic neuronal... 
Neurology | fibroblast growth factor 18 | 6-OHDA | dopamine | Parkinson’s disease
Journal Article